Group 1 - The company Shanghai Youningwei Biotechnology Co., Ltd. will participate in the 2025 Shanghai Listed Companies Collective Reception Day and Mid-Year Performance Briefing [1][2] - The event will be held online on September 19, 2025, from 15:00 to 17:00, allowing investors to engage with the company's management [2] - Key company representatives, including the chairman and general manager, independent directors, and the financial director, will address investor concerns regarding the company's half-year performance, governance, and strategic development [2] Group 2 - Investors can submit questions for discussion until 14:00 on September 19, 2025, through a designated webpage [2] - The company aims to enhance communication with investors and ensure that the discussion is relevant to their interests [2][3]

本次活动将采用网络远程的方式举行，投资者可登录 "全景路演"网站 (http://rs.p5w.net)；或关注微信公众号(名称:全景财经);或下载全景路演 APP，参 与本次互动交流。 活动时间为 2025 年 9 月 19 日(周五)15:00-17:00。届时公司董事长兼总经理 冷兆武先生，独立董事石磊先生、独立董事蔡鸿亮先生、独立董事金宇超先生、 董事会秘书祁艳芳女士和财务总监唐敏女士，将在线就公司 2025 半年度业绩、 公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与！ 为充分尊重投资者，提升交流的针对性，投资者可于 2025 年 9 月 19 日（周 五）14：00 前访问 http://ir.p5w.net/zj/进入问题征集专题页面。公司将在本次集体 接待日上，对投资者普遍关注的问题进行回答。 证券代码：301166 证券简称：优宁维 公告编号：2025-075 上海优宁维生物科技股份有限公司 关于参加 2025 年上海辖区上市公司集体接待日暨 中报业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、 ...

Group 1 - The company Shanghai Youningwei Biotechnology Co., Ltd. has signed an agreement to acquire a 15 million RMB stake in the Shanghai Hongsheng Houde Private Equity Fund Partnership, becoming a limited partner with a 2.6283% share of the total capital contribution [2][3] - The Hongsheng Houde fund has completed the necessary business registration changes and received a registration notice from the Shanghai Municipal Market Supervision Administration [3] - The fund was established on March 15, 2023, with a total capital contribution of 570.71 million RMB, and its main business activities include private equity investment and asset management [3][5] Group 2 - The company will continue to monitor the progress of the partnership and fulfill its information disclosure obligations in accordance with relevant laws and regulations [3]

Group 1 - The company, You Ning Wei, announced on September 4 that it signed a fund share transfer agreement with Shanghai Rui Ang Gene Technology Co., Ltd. and Shanghai Hongsheng Junhao Equity Investment Fund Management Co., Ltd. on August 18, 2025 [2] - The agreement involves the acquisition of a 15 million yuan stake in the Hongsheng Houde Private Investment Fund Partnership, making the company one of the limited partners in the fund [2] - After the transfer, the company's subscribed amount will account for 2.6283% of the total subscribed capital of the partnership [2]

Investment Overview - Shanghai Youningwei Biotechnology Co., Ltd. signed a fund share transfer agreement on August 18, 2025, to acquire a property share of 15 million RMB from Shanghai Ruian Gene Technology Co., Ltd. [1] - After the transfer, the company holds a 2.6283% stake in the Hongsheng Houde Private Investment Fund Partnership [1] Investment Progress - The Hongsheng Houde Private Investment Fund has completed the necessary business registration changes and received a registration notice from the Shanghai Municipal Market Supervision Administration [1] - The fund's basic registration information includes a total contribution amount of 570.71 million RMB and was established on March 15, 2023 [1] Other Information - The company will continue to monitor the partnership's progress and fulfill its information disclosure obligations in accordance with relevant laws and regulations [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、对外投资情况概述 上海优宁维生物科技股份有限公司（以下简称"公司"）于2025年8月18日与 上海睿昂基因科技股份有限公司（以下简称"睿昂基因"）、上海弘盛君浩股权 投资基金管理有限公司共同签署了《基金份额转让协议》，同意受让睿昂基因持 有的上海弘盛厚德私募投资基金合伙企业（有限合伙）（以下简称"弘盛厚德" 或"合伙企业"）1,500万元财产份额。本次转让完成后，公司成为弘盛厚德有限 合伙人之一，投资后公司认缴额占合伙企业总认缴额的2.6283%。具体内容详见 披露于巨潮咨询网（http://www.cninfo.com.cn）的《关于受让投资基金份额暨对 外投资的公告》（公告编号：2025-064）。 二、对外投资进展情况 近日，弘盛厚德已完成相关工商变更登记手续，并取得上海市市场监督管理 局下发的《登记通知书》。本次工商变更登记后，弘盛厚德的基本登记信息如下： 证券代码：301166 证券简称：优宁维 公告编号：2025-074 上海优宁维生物科技股份有限公司 关于受让投资基金份额暨对外投资的进展公告 主 ...

Group 1 - The company announced that as of August 31, 2025, it has repurchased a total of 0 shares through a dedicated securities account for share buybacks, representing 0% of the total share capital [1] - The company has not yet implemented the current share buyback plan [1] - The share repurchase plan complies with relevant laws, regulations, and the company's share buyback scheme [1]

证券代码：301166 证券简称：优宁维 公告编号：2025-072 上海优宁维生物科技股份有限公司 关于回购公司股份的进展公告 公司回购股份符合《深圳证券交易所上市公司自律监管指引第 9 号——回购 股份》及公司回购股份方案的相关规定，具体如下： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司(以下简称"公司")于 2025 年 4 月 10 日召 开第四届董事会第四次会议、第四届监事会第四次会议，于 2025 年 5 月 13 日召 开 2024 年度股东大会，审议通过了《关于回购公司股份方案的议案》，同意公 司使用不低于人民币 1,500 万元（含本数），不高于人民币 3,000 万元（含本数） 的自有资金以集中竞价交易方式回购公司部分无限售条件的 A 股流通股，用于 注销并减少注册资本，回购价格不超过人民币 44 元/股（含本数，下同），回购 期限自公司 2024 年度股东大会审议通过本次回购股份方案之日起 12 个月内。具 体内容详见公司于 2025 年 4 月 14 日及 2025 年 5 月 13 日刊登在巨潮资讯 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-073 上海优宁维生物科技股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"或"优宁维"）于 2025 年 2 月 17 日召开第四届董事会第三次会议和第四届监事会第三次会议，2025 年 3 月 7 日召开 2025 年第二次临时股东大会，审议通过了《关于使用闲置募集资 金及自有资金进行现金管理的议案》，同意公司及并表范围内的子孙公司在不影 响募集资金投资项目建设、不影响公司正常生产经营及确保资金安全的情况下， 使用不超过人民币 30,000 万元（含本数）的闲置募集资金及不超过人民币 150,000 万元（含本数）的自有资金进行现金管理，使用期限自 2025 年 3 月 9 日起 12 个月内有效。公司独立董事和保荐机构均发表了同意意见。具体内容详见公司分 别于 2025 年 2月 19 日和 2025年 3 月 8日刊载于巨潮资讯网（www.cninfo.com.cn） 的相关公告。 现将公 ...

Group 1 - The core viewpoint of the news is that You Ning Wei's stock has experienced a decline, with significant changes in financing and shareholder metrics [1][2] - On August 27, You Ning Wei's stock fell by 4.29%, with a trading volume of 91.43 million yuan. The net financing buy was -3.55 million yuan, indicating a higher level of financing repayment compared to buying [1] - As of August 27, the total financing and securities lending balance for You Ning Wei was 52.22 million yuan, which is 1.86% of its market capitalization, indicating a low financing balance compared to the past year [1] Group 2 - As of June 30, the number of shareholders for You Ning Wei increased by 5.02% to 11,400, with an average of 4,994 circulating shares per person, up 31.33% [2] - For the first half of 2025, You Ning Wei reported a revenue of 505 million yuan, a year-on-year decrease of 8.63%, and a net profit attributable to shareholders of -13.38 million yuan, a significant decline of 188.64% [2] - Since its A-share listing, You Ning Wei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed over the past three years [3]